CN110291402B - 鉴定肽表位的方法、结合此类表位的分子和相关用途 - Google Patents

鉴定肽表位的方法、结合此类表位的分子和相关用途 Download PDF

Info

Publication number
CN110291402B
CN110291402B CN201780051883.0A CN201780051883A CN110291402B CN 110291402 B CN110291402 B CN 110291402B CN 201780051883 A CN201780051883 A CN 201780051883A CN 110291402 B CN110291402 B CN 110291402B
Authority
CN
China
Prior art keywords
mhc
antigen
cell
peptide
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780051883.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110291402A (zh
Inventor
S·U·塔瑞恩
J·萨松
M·弗洛里奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Juno Therapeutics Inc
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of CN110291402A publication Critical patent/CN110291402A/zh
Application granted granted Critical
Publication of CN110291402B publication Critical patent/CN110291402B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
CN201780051883.0A 2016-06-27 2017-06-27 鉴定肽表位的方法、结合此类表位的分子和相关用途 Expired - Fee Related CN110291402B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355211P 2016-06-27 2016-06-27
US62/355,211 2016-06-27
PCT/US2017/039596 WO2018005559A1 (en) 2016-06-27 2017-06-27 Method of identifying peptide epitopes, molecules that bind such epitopes and related uses

Publications (2)

Publication Number Publication Date
CN110291402A CN110291402A (zh) 2019-09-27
CN110291402B true CN110291402B (zh) 2023-09-01

Family

ID=59363220

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780051883.0A Expired - Fee Related CN110291402B (zh) 2016-06-27 2017-06-27 鉴定肽表位的方法、结合此类表位的分子和相关用途

Country Status (7)

Country Link
US (1) US20200182884A1 (enExample)
EP (1) EP3475446A1 (enExample)
JP (1) JP6987134B2 (enExample)
CN (1) CN110291402B (enExample)
CA (1) CA3028002A1 (enExample)
MA (1) MA45455A (enExample)
WO (1) WO2018005559A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3351636T (pt) 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
LT2964769T (lt) * 2013-03-05 2018-12-10 Oregon Health & Science University Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
NZ728208A (en) 2014-07-16 2018-07-27 Univ Oregon Health & Science Human cytomegalovirus comprising exogenous antigens
EA201791806A1 (ru) 2015-02-10 2017-12-29 Орегон Хелс Энд Сайенс Юниверсити Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов
US10688164B2 (en) 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
WO2018075591A1 (en) 2016-10-18 2018-04-26 Oregon Health & Science University Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
CN110809716B (zh) 2017-02-12 2023-07-07 百欧恩泰美国公司 基于hla的方法和组合物及其用途
EP3568469A4 (en) * 2017-02-21 2020-11-11 Eutilex Co., Ltd. COMPOSITIONS OF CAR-T CELLS DIRECTED AGAINST HLA-DR AND THEIR MANUFACTURING AND USE PROCEDURES
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
CA3084674A1 (en) 2017-12-23 2019-06-27 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use
CN112351795A (zh) * 2018-02-23 2021-02-09 安贝科思生物制剂公司 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
EP3539552A1 (en) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
US10557216B2 (en) * 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
CN112512538A (zh) * 2018-05-18 2021-03-16 国家儿童医疗中心 改进的靶向t细胞疗法
AU2019301750A1 (en) 2018-07-12 2021-01-28 Board Of Regents, The University Of Texas System Molecular neighborhood detection by oligonucleotides
JP7539161B2 (ja) 2018-08-10 2024-08-23 ユーティレックス カンパニー リミテッド Ｈｌａ－ｄｒに結合するキメラ抗原受容体およびｃａｒ－ｔ細胞
WO2020037046A1 (en) * 2018-08-14 2020-02-20 Board Of Regents, The University Of Texas System Single molecule sequencing peptides bound to the major histocompatibility complex
WO2020072907A1 (en) 2018-10-05 2020-04-09 Board Of Regents, The University Of Texas System Solid-phase n-terminal peptide capture and release
WO2020117852A1 (en) 2018-12-03 2020-06-11 Rubius Therapeutics, Inc. Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use
CA3124457A1 (en) 2018-12-21 2020-06-25 Biontech Us Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
DE19913048T1 (de) * 2019-01-31 2022-01-27 Nantbio, Inc. Mrna-display-antikörper-bibliothek und verfahren
JP2022521738A (ja) 2019-02-20 2022-04-12 ルビウス セラピューティクス， インコーポレイテッド 負荷可能な抗原提示ポリペプチドを含む操作された赤血球系細胞および使用方法
CN109913414A (zh) * 2019-03-21 2019-06-21 吉林省银丰生物工程技术有限公司 肝癌afp特异性人工抗原递呈细胞诱导试剂盒
TW202118792A (zh) * 2019-07-26 2021-05-16 美商健生生物科技公司 抗hk2嵌合抗原受體(car)
JP2022543687A (ja) * 2019-08-09 2022-10-13 イマティクス ユーエス，アイエヌシー． ペプチド質量分析断片化を予測するための方法
WO2021087851A1 (zh) * 2019-11-07 2021-05-14 苏州工业园区唯可达生物科技有限公司 一种重组病毒载体、包含其的免疫组合物以及用途
EP4103696A1 (en) 2020-02-10 2022-12-21 Rubius Therapeutics, Inc. Engineered erythroid cells including hla-g polypeptides and methods of use thereof
CN111116716B (zh) * 2020-03-03 2022-03-01 中国医科大学 一种与骨髓瘤细胞高表达抗原hla-e特异性结合的多肽及其用途
CN111429965B (zh) * 2020-03-19 2023-04-07 西安交通大学 一种基于多连体特征的t细胞受体对应表位预测方法
AU2021264068A1 (en) * 2020-04-30 2022-12-08 The Translational Genomics Research Institute Neoantigen-informed tumor-infiltrating lymphocyte cancer immunotherapy
CN112285347B (zh) * 2020-09-30 2023-12-22 西北农林科技大学 一种猪血清样中病原抗体elisa检测试剂盒
EP4463572A4 (en) * 2022-01-13 2026-04-08 Massachusetts Inst Technology ANALYSIS, SCREENING AND SELECTION OF FUNCTIONS OF SOLUBBLE PROTEINS IN CELLULAR BANK OF SECRETED PROTEINS
EP4479156A1 (en) * 2022-02-19 2024-12-25 Waters Technologies Corporation Novel size exclusion chromatography column technologies for analysis of crispr molecules
US20260126450A1 (en) * 2022-10-12 2026-05-07 Massachusetts Institute Of Technology Library-scale methods for polypeptide functional analysis
WO2025111600A1 (en) * 2023-11-22 2025-05-30 Calico Life Sciences Llc Compositions and methods for lipidated peptide-based modulators of hla-e
WO2025174878A1 (en) * 2024-02-13 2025-08-21 Abata Therapeutics, Inc. Patient selection and treatment for multiple sclerosis
US20250297263A1 (en) * 2024-03-22 2025-09-25 Massachusetts Institute Of Technology One-step construction of allogenic car-nk cells with increased anti-tumor cytotoxicity and resistance to host cell rejection

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067761A1 (en) * 1999-05-06 2000-11-16 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
CN1367830A (zh) * 1998-10-05 2002-09-04 路德维哥癌症研究院 癌症相关抗原及其应用
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
WO2004015395A2 (en) * 2002-08-13 2004-02-19 National Jewish Medical And Research Center Method for identifying mhc-presented peptide epitopes for t cells
CN1561229A (zh) * 2001-08-21 2005-01-05 马里兰大学生物技术研究所 病毒外壳蛋白/受体嵌合体及使用方法
WO2014138209A1 (en) * 2013-03-05 2014-09-12 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting
CN104404040A (zh) * 2014-12-11 2015-03-11 浙江大学 抗HCMV UL128基因82-102位点的siRNA序列及应用
WO2015143558A1 (en) * 2014-03-27 2015-10-01 British Columbia Cancer Agency Branch T-cell epitope identification

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983001A (en) 1972-05-10 1976-09-28 Ceskoslovenska Akademie Ved Isolation of biologically active compounds by affinity chromatography
US4213860A (en) 1976-06-30 1980-07-22 Board of Regents, State of Florida for and on behalf of the University of Florida Affinity chromatography and substrate useful therefor
GB1602432A (en) 1976-12-15 1981-11-11 Atomic Energy Authority Uk Affinity chromatography
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4175182A (en) 1978-07-03 1979-11-20 Research Corporation Separation of high-activity heparin by affinity chromatography on supported protamine
GB2097279B (en) 1981-04-27 1984-08-01 Health Lab Service Board Affinity chromatography in presence of metal ions
GB2097280B (en) 1981-04-27 1984-11-07 Public Helath Lab Service Boar High pressure liquid affinity chromatography
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5821058A (en) 1984-01-16 1998-10-13 California Institute Of Technology Automated DNA sequencing technique
US5171534A (en) 1984-01-16 1992-12-15 California Institute Of Technology Automated DNA sequencing technique
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4811218A (en) 1986-06-02 1989-03-07 Applied Biosystems, Inc. Real time scanning electrophoresis apparatus for DNA sequencing
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0277773A1 (en) 1987-01-30 1988-08-10 The Board Of Trustees Of The Leland Stanford Junior University Hybrid cytomegalovirus (CMV) and vaccine
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5149625A (en) 1987-08-11 1992-09-22 President And Fellows Of Harvard College Multiplex analysis of DNA
JP2650159B2 (ja) 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー 核酸増幅方法
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
SE8801070D0 (sv) 1988-03-23 1988-03-23 Pharmacia Ab Method for immobilizing a dna sequence on a solid support
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US4962020A (en) 1988-07-12 1990-10-09 President And Fellows Of Harvard College DNA sequencing
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5043062A (en) 1989-02-21 1991-08-27 Eastman Kodak Company High performance affinity chromatography column comprising non-porous, nondisperse polymeric packing material
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
CA2079802C (en) 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE4123760C2 (de) 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
GB9208733D0 (en) 1992-04-22 1992-06-10 Medical Res Council Dna sequencing method
IL106610A0 (en) 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
ATE267877T1 (de) 1993-01-07 2004-06-15 Sequenom Inc Dns - sequenzierung durch massenspektronomie
US5374527A (en) 1993-01-21 1994-12-20 Applied Biosystems, Inc. High resolution DNA sequencing method using low viscosity medium
US5989565A (en) 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
CA2155186A1 (en) 1993-02-01 1994-08-18 Kevin M. Ulmer Methods and apparatus for dna sequencing
SG49008A1 (en) 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
JPH08507926A (ja) 1993-03-19 1996-08-27 シーケノム・インコーポレーテツド エキソヌクレアーゼ分解を介した質量分析法によるｄｎａ配列決定
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5654419A (en) 1994-02-01 1997-08-05 The Regents Of The University Of California Fluorescent labels and their use in separations
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US5840306A (en) 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5721354A (en) 1995-03-31 1998-02-24 Aviron Human cytomegalovirus DNA sequences
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
DK0862656T3 (da) 1995-11-21 2001-04-09 Univ Yale Unimolekylær segmentamplifikation og -detektering
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5846727A (en) 1996-06-06 1998-12-08 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Microsystem for rapid DNA sequencing
GB9618050D0 (en) 1996-08-29 1996-10-09 Cancer Res Campaign Tech Global amplification of nucleic acids
EP1477561B1 (en) 1996-10-17 2008-12-10 Mitsubishi Chemical Corporation Molecule assigning genotype to phenotype and use thereof
US5858671A (en) 1996-11-01 1999-01-12 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
US6258533B1 (en) 1996-11-01 2001-07-10 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
US5876934A (en) 1996-12-18 1999-03-02 Pharmacia Biotech Inc. DNA sequencing method
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
NZ507886A (en) 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CA2350417C (en) 1998-12-02 2010-02-09 Bristol-Myers Squibb Company Dna-protein fusions and uses thereof
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
US6385581B1 (en) 1999-05-05 2002-05-07 Stanley W. Stephenson System and method of providing emotive background sound to text
EP1054018B1 (en) 1999-05-18 2009-01-28 Dyax Corp. Fab fragment libraries and methods for their use
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US6132997A (en) 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
CA2377468C (en) 1999-07-27 2010-04-20 Phylos, Inc. Peptide acceptor ligation methods
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US6692954B1 (en) 2000-11-03 2004-02-17 The Scripps Research Institute Generation of human cytomegalovirus yeast artificial chromosome recombinants
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
WO2002066629A2 (en) 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
EP1809669A2 (en) 2004-10-01 2007-07-25 Avidex Ltd T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
US8668564B2 (en) 2005-01-24 2014-03-11 Solution Champion Limited Jackpot method and system
US8361473B2 (en) 2007-03-29 2013-01-29 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
KR20110036638A (ko) 2008-07-25 2011-04-07 리차드 더블유. 와그너 단백질 스크리닝 방법
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
US8580276B2 (en) * 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
SG177025A1 (en) 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
PT3351636T (pt) * 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3798236B1 (en) 2011-03-15 2022-08-10 X-Body, Inc. Antibody screening methods
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
ES2785081T3 (es) 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
NZ741124A (en) 2012-07-27 2019-11-29 Univ Illinois Engineering t-cell receptors
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US10738278B2 (en) * 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
NZ728208A (en) * 2014-07-16 2018-07-27 Univ Oregon Health & Science Human cytomegalovirus comprising exogenous antigens
EA201791806A1 (ru) 2015-02-10 2017-12-29 Орегон Хелс Энд Сайенс Юниверсити Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1367830A (zh) * 1998-10-05 2002-09-04 路德维哥癌症研究院 癌症相关抗原及其应用
WO2000067761A1 (en) * 1999-05-06 2000-11-16 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
CN1561229A (zh) * 2001-08-21 2005-01-05 马里兰大学生物技术研究所 病毒外壳蛋白/受体嵌合体及使用方法
WO2004015395A2 (en) * 2002-08-13 2004-02-19 National Jewish Medical And Research Center Method for identifying mhc-presented peptide epitopes for t cells
WO2014138209A1 (en) * 2013-03-05 2014-09-12 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting
WO2015143558A1 (en) * 2014-03-27 2015-10-01 British Columbia Cancer Agency Branch T-cell epitope identification
CN104404040A (zh) * 2014-12-11 2015-03-11 浙江大学 抗HCMV UL128基因82-102位点的siRNA序列及应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Conformational B-cell epitope prediction method based on antigen preprocessing and mimotopes analysis;Pingping Sun 等;Biomed Res Int .;2015;全文 *

Also Published As

Publication number Publication date
JP2019520089A (ja) 2019-07-18
MA45455A (fr) 2019-05-01
CA3028002A1 (en) 2018-01-04
JP6987134B2 (ja) 2021-12-22
WO2018005559A1 (en) 2018-01-04
US20200182884A1 (en) 2020-06-11
EP3475446A1 (en) 2019-05-01
CN110291402A (zh) 2019-09-27

Similar Documents

Publication Publication Date Title
JP7340638B2 (ja) Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
JP6987134B2 (ja) ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途
KR102764123B1 (ko) Τ 세포 수용체 및 이를 발현하는 조작된 세포
US20210363258A1 (en) Hpv-specific binding molecules
KR102804498B1 (ko) 입양 세포 치료를 위한 방법 및 조성물
EP3704229B1 (en) Process for producing a t cell composition
EP3664820B1 (en) Methods for producing genetically engineered cell compositions and related compositions
JP2023036841A (ja) キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
US20180355014A1 (en) Modified chimeric receptors and related compositions and methods
CN115175934A (zh) 靶向共有新抗原的抗原结合蛋白
EP3322801A1 (en) Engineered cells for adoptive cell therapy
JP2024119881A (ja) 操作されたメモリー様ｎｋ細胞を作製するための方法およびその組成物
JP2024544903A (ja) Ｈｐｖ１６ ｅ７抗原を認識する結合タンパク質及びその使用
CN117321417A (zh) 确定治疗性细胞组合物的效力的方法
HK40074466A (en) Mhc-e restricted epitopes, binding molecules and related methods and uses
HK40007215B (en) Mhc-e restricted epitopes, binding molecules and related methods and uses
HK40007215A (en) Mhc-e restricted epitopes, binding molecules and related methods and uses
US20240010745A1 (en) Methods and compositions for depleting natural killer cells and uses thereof in cellular therapies
HK40122442A (en) Process for generating therapeutic compositions of engineered cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230901

CF01 Termination of patent right due to non-payment of annual fee